Q32 Bio Q4 net income hits USD 57.73 million as R&D expenses fall 69% to USD 3.32 million

Reuters

Mar 10

Q32 Bio Q4 net income hits USD 57.73 million as R&D expenses fall 69% to USD 3.32 million

Q32 Bio reported Q4 net income of USD 57.73 million, compared with a net loss a year earlier. Research and development expense fell 69% to USD 3.32 million, primarily due to lower bempikibart development and manufacturing costs, reduced ADX-097 spend after discontinuing its Phase 2 renal basket trial, and lower personnel-related costs. Cash and cash equivalents were USD 48.3 million at Dec. 31, and the company said this, plus gross proceeds from a USD 10.5 million registered direct offering and guaranteed near-term milestone payments from the ADX-097 sale, is expected to fund operations into Q4 2027. Q32 Bio said it completed enrollment in Part B of its SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata and increased the trial size to 33 patients, with 36-week topline data expected in mid-2026. CEO Jodie Morrison said the company is encouraged by pharmacokinetic data and emerging signs of clinical activity in Part B.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100659PR_NEWS_USPR_____NE05856) on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618934946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618934946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618934946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618934946","market":"nz","top_or_hot":-1,"title":"Q32 Bio Q4 net income hits USD 57.73 million as R&D expenses fall 69% to USD 3.32 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Q32 Bio Q4 net income hits USD 57.73 million as R&amp;D expenses fall 69% to USD 3.32 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Q32 Bio reported Q4 net income of USD 57.73 million, compared with a net loss a year earlier. Research and development expense fell 69% to USD 3.32 million, primarily due to lower bempikibart development and manufacturing costs, reduced ADX-097 spend after discontinuing its Phase 2 renal basket trial, and lower personnel-related costs. Cash and cash equivalents were USD 48.3 million at Dec. 31, and the company said this, plus gross proceeds from a USD 10.5 million registered direct offering and guaranteed near-term milestone payments from the ADX-097 sale, is expected to fund operations into Q4 2027. Q32 Bio said it completed enrollment in Part B of its SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata and increased the trial size to 33 patients, with 36-week topline data expected in mid-2026. CEO Jodie Morrison said the company is encouraged by pharmacokinetic data and emerging signs of clinical activity in Part B.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/QTTB\">Q32 Bio Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100659PR_NEWS_USPR_____NE05856) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Q32 Bio Q4 net income hits USD 57.73 million as R&D expenses fall 69% to USD 3.32 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQ32 Bio Q4 net income hits USD 57.73 million as R&D expenses fall 69% to USD 3.32 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Q32 Bio Q4 net income hits USD 57.73 million as R&amp;D expenses fall 69% to USD 3.32 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Q32 Bio reported Q4 net income of USD 57.73 million, compared with a net loss a year earlier. Research and development expense fell 69% to USD 3.32 million, primarily due to lower bempikibart development and manufacturing costs, reduced ADX-097 spend after discontinuing its Phase 2 renal basket trial, and lower personnel-related costs. Cash and cash equivalents were USD 48.3 million at Dec. 31, and the company said this, plus gross proceeds from a USD 10.5 million registered direct offering and guaranteed near-term milestone payments from the ADX-097 sale, is expected to fund operations into Q4 2027. Q32 Bio said it completed enrollment in Part B of its SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata and increased the trial size to 33 patients, with 36-week topline data expected in mid-2026. CEO Jodie Morrison said the company is encouraged by pharmacokinetic data and emerging signs of clinical activity in Part B.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/QTTB\">Q32 Bio Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100659PR_NEWS_USPR_____NE05856) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL8VjNnR:1","article_id":"2618934946","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618934946","pubTimestamp":1773140442,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Q32 Bio reported Q4 net income of USD 57.73 million, compared with a net loss a year earlier. Research and development expense fell 69% to USD 3.32 million, primarily due to lower bempikibart development and manufacturing costs, reduced ADX-097 spend after discontinuing its Phase 2 renal basket trial, and lower personnel-related costs. Cash and cash equivalents were USD 48.3 million at Dec. 31, and the company said this, plus gross proceeds from a USD 10.5 million registered direct offering and guaranteed near-term milestone payments from the ADX-097 sale, is expected to fund operations into Q4 2027. Q32 Bio said it completed enrollment in Part B of its SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata and increased the trial size to 33 patients, with 36-week topline data expected in mid-2026. CEO Jodie Morrison said the company is encouraged by pharmacokinetic data and emerging signs of clinical activity in Part B.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QTTB":"Q32 Bio Inc."},"translate_title":"Q32 Bio第四季度净利润达到5773万美元，研发费用下降69%至332万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTTB":0.9},"content_text":"Q32 Bio Q4 net income hits USD 57.73 million as R&D expenses fall 69% to USD 3.32 million\n    \n\n        Q32 Bio reported Q4 net income of USD 57.73 million, compared with a net loss a year earlier. Research and development expense fell 69% to USD 3.32 million, primarily due to lower bempikibart development and manufacturing costs, reduced ADX-097 spend after discontinuing its Phase 2 renal basket trial, and lower personnel-related costs. Cash and cash equivalents were USD 48.3 million at Dec. 31, and the company said this, plus gross proceeds from a USD 10.5 million registered direct offering and guaranteed near-term milestone payments from the ADX-097 sale, is expected to fund operations into Q4 2027. Q32 Bio said it completed enrollment in Part B of its SIGNAL-AA Phase 2a trial of bempikibart in alopecia areata and increased the trial size to 33 patients, with 36-week topline data expected in mid-2026. CEO Jodie Morrison said the company is encouraged by pharmacokinetic data and emerging signs of clinical activity in Part B.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100659PR_NEWS_USPR_____NE05856) on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}